Schizophrenia: a review of neuropharmacology
The last few decades have seen significant advances in our understanding of the neurochemical basis of schizophrenia.
To describe the neurotransmitter systems and nerve circuits implicated in schizophrenia; to compare the neuropharmacology of typical and atypical anti-psychotic agents; and to describe recent developments in the pharmacological treatment of schizophrenia.
Relevant pharmacological, neurophysiological and psychiatric literature was examined and reviewed.
Schizophrenia is associated with abnormalities of multiple neurotransmitter systems, including dopamine, serotonin, gamma-aminobutyric acid and glutamate. Typical and atypical antipsychotic agents differ in their receptorbinding affinities, which are related to their differing side-effect profiles. Novel therapeutic strategies include normalisation of synaptic dopamine or serotonin levels, serotonin receptor antagonism and modulation of cerebral protein synthesis.
The ideal treatment for schizophrenia may not be a single pharmacological agent but several agents that match the different expressions of the illness, in combination with psycho-social interventions.
KeywordsSchizophrenia Clozapine Olanzapine Quetiapine Ventral Tegmental Area
- 3.Daly A, Walsh D. Irish Psychiatric Services: Activities 2000. Dublin: Health Research Board, 2001.Google Scholar
- 4.Kahn, Rene S, Davis Kenneth L. New Developments in Dopamine and Schizophrenia. The American College Of Neuropsychopharmacology 2000.Google Scholar
- 5.Gelder M, Gath D, Mayou R, Cowen P. Oxford Textbook of Psychiatry (3rd edition), Oxford University Press, Oxford 1996.Google Scholar
- 6.Abi-Dargham A, Guo NN, Lombardo I et al. Selective Upregulation Of Prefrontal D1 Receptors In Schizophrenia Predicts Poor Working Memory Performance. NeuroReceptor Mapping 2002 Meeting. Elsevier Science, New York 2002.Google Scholar
- 7.Rang HP, Dale MM, Ritter JM et al. Pharmacology. Churchill Livingstone, New York 1999.Google Scholar
- 8.Roth BL, Meltzer HY. The role of serotonin in schizophrenia. The American College Of Neuropsychopharmacology, New York 2000.Google Scholar
- 9.Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favourable molecular targets for cognitive enhancement in schizophrenia and other disorders.Psychopharmacol (Berl) 2004; 174: 17–24.Google Scholar
- 10.Fan JB, Sklar P. Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia.Mol Psychiatry 2004 Aug 31 [Epub ahead of print] (available at http://www.nature.com/mp/journal/vaop/ncurrent/).Google Scholar
- 11.Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics, McGraw Hill, New York 1996.Google Scholar
- 12.Kaplan VA, Sadcock BJ. Comprehensive Textbook of Psychiatry. Lippencott Williams & Wilkins, New York 1995.Google Scholar
- 20.Bunney G. B., Bunney Jr., W.E., Carlsson A. Schizophrenia and Glutamate: An update. The American College Of Neuropsychopharmacology, New York 2000.Google Scholar
- 21.McEvoy JP, Scheifler Pl, Frances A. Expert consensus guideline series. Treatment of schizophrenia.J Clin Psychiatry 1999; 60 Suppl 11: 3–80.Google Scholar
- 23.Meltzer HY. Atypical antipsychotic drugs. The American College Of Neuropsychopharrnacology, New York 2000.Google Scholar